- Home
- BMRN vs FFIV Comparison
BMRN vs FFIV Comparison
Compare BMRN & FFIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRN
- FFIV
- Stock Information
- Founded
- BMRN 1996
- FFIV 1996
- Country
- BMRN United States
- FFIV United States
- Employees
- BMRN N/A
- FFIV N/A
- Industry
- BMRN Biotechnology: Pharmaceutical Preparations
- FFIV Computer Communications Equipment
- Sector
- BMRN Health Care
- FFIV Telecommunications
- Exchange
- BMRN Nasdaq
- FFIV Nasdaq
- Market Cap
- BMRN 13.7B
- FFIV 14.8B
- IPO Year
- BMRN 1999
- FFIV 1999
- Fundamental
- Price
- BMRN $71.44
- FFIV $263.88
- Analyst Decision
- BMRN Buy
- FFIV Hold
- Analyst Count
- BMRN 22
- FFIV 10
- Target Price
- BMRN $94.00
- FFIV $289.00
- AVG Volume (30 Days)
- BMRN 1.5M
- FFIV 571.6K
- Earning Date
- BMRN 04-23-2025
- FFIV 04-28-2025
- Dividend Yield
- BMRN N/A
- FFIV N/A
- EPS Growth
- BMRN 153.71
- FFIV 31.07
- EPS
- BMRN 2.21
- FFIV 10.05
- Revenue
- BMRN $2,853,915,000.00
- FFIV $2,890,012,000.00
- Revenue This Year
- BMRN $12.23
- FFIV $9.02
- Revenue Next Year
- BMRN $9.90
- FFIV $4.01
- P/E Ratio
- BMRN $32.37
- FFIV $26.26
- Revenue Growth
- BMRN 17.97
- FFIV 3.02
- 52 Week Low
- BMRN $60.63
- FFIV $159.01
- 52 Week High
- BMRN $94.85
- FFIV $313.00
- Technical
- Relative Strength Index (RSI)
- BMRN 55.89
- FFIV 38.14
- Support Level
- BMRN $69.60
- FFIV $270.36
- Resistance Level
- BMRN $73.18
- FFIV $278.85
- Average True Range (ATR)
- BMRN 1.64
- FFIV 6.92
- MACD
- BMRN -0.15
- FFIV 0.43
- Stochastic Oscillator
- BMRN 63.45
- FFIV 35.47
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
About FFIV F5 Inc.
F5 is a market leader in the application delivery controller market. The company sells products for security, application performance, and automation. Its three customer verticals are enterprises, service providers, and government entities. Revenue is evenly split between its services business and products business with revenue trending toward products due to software adoption. The Seattle-based firm was incorporated in 1996, and went public in 1999.